

Programme
Virtual CVOT Summit 2023
www.cvot.org

Thursday, 30 November 2023

Virtual

15:00 – 15:10 CET

Welcome and Introduction
 Schnell O (Munich, Germany)

15:10 – 16:50 CET

Update on Clinical Guidelines and network Meta-Analyses
 Chairs: Groop P-H (Helsinki, Finland), Rydén L (Stockholm, Sweden)

15:10 – 15:25	Management of CKD in 2023: an update of guidelines Groop P-H (Helsinki, Finland)
15:25 – 15:40	What`s new in the ESC “Diabetes and the Heart” and “Heart Failure” Guidelines 2023 Marx N (Aachen, Germany)
15:40 – 15:50	Discussion
15:50 – 16:05	Treatment for Type 2 Diabetes: systematic review and network meta-analysis for the creation of living guidelines Rydén L (Stockholm, Sweden)
16:05 – 16:20	Join the Alliance for Living Evidence (Alive)! Tendal Jeppesen B (Copenhagen, Denmark)
16:20 – 16:35	Strengthening the recognition of minority groups in clinical guidelines for diabetes Gavin JR (Atlanta, USA)
16:35 – 16:50	Discussion

16:50 – 17:00 CET Break

17:00 – 18:30 CET

Making sense of Patient-Reported Outcomes (PROs) and why they matter

Chairs: Barnard-Kelly K (Hampshire, UK), Lalic N (Belgrade, Serbia)

17:00 – 17:15	Consensus statement on PROs - why, how and what does it matter? Barnard-Kelly K (Hampshire, UK)
17:15 – 17:30	IDF perspective on PROs Schwarz P (Dresden, Germany)
17:30 – 17:45	PROs: What are governments doing in this space and how do they influence policy? Taylor B (Tampa, USA)
17:45 – 18:00	Patient’s perspectives on PROs Huntley G (Indianapolis, USA)
18:00 – 18:30	Discussion

18:30 – 18:45 CET Break

18:45 – 19:45 CET	
Keynote lectures: Overcoming boundaries - new options arise Chair: Giorgino F (Bari, Italy), Schumm-Draeger P (Munich, Germany)	
18:45 – 19:05	Multireceptor drugs for obesity: a new emerging universe Müller T (Munich, Germany)
19:05 – 19:15	Discussion
19:15 – 19:35	New horizons for CGM in diabetes: further building a key pillar of diabetes management Battelino T (Ljubljana, Slovenia)
19:35 – 19:45	Discussion

19:45 – 20:45 CET	
Oral Presentations – Part 1 Chairs: Mankovsky B (Kyiv, Ukraine), Schnell O (Munich, Germany)	
19:45 – 20:45 CET	OP 1: Lipid-Lowering Treatments and Risk of Cardiovascular Events in Over 9000 Patients From 14 European Countries: 1-year Prospective Follow-Up of the SANTORINI Registry Aguiar C (Carnaxide, Portugal)
	OP 2: Benefit of Dual Therapy With GLP-1 RA and SGLT2i on Cardiovascular Outcomes in Type 2 Diabetes Kvist K (Søborg, Denmark)
	OP 3: Tirzepatide Reduces Albuminuria in Patients With Type 2 Diabetes: Post-Hoc Pooled Analysis of SURPASS 1-5 Ranta K (Helsinki, Finland)
	OP 4: Impact of Finerenone on Chronic Kidney Disease Progression in Chinese Patients With Type 2 Diabetes: FIGARO-DKD Subgroup Analysis Brinker M (Wuppertal, Germany)
	OP 5: A cross-sectional survey on CKD diagnosis and management Rötzer R (Munich, Germany)

20:45 CET

Closing of Day 1

Friday, 1 December 2023

Virtual

08:30 – 09:50 CET

Prevention of Type 1 Diabetes and its complications

Chairs: Hummel M (Munich, Germany), Malik RA (Doha, Qatar)

08:30 – 08:45	Type 1 Diabetes: early detection and preventive approaches Larsson HE (Lund, Sweden)
08:45 – 09:00	Teplizumab – Delaying the onset of Type 1 Diabetes Mathieu C (Leuven, Belgium)
09:00 – 09:15	Treatment strategies for neuropathy in Type 1 Diabetes Tesfaye S (Sheffield, UK)
09:15 – 09:30	Preventing and delaying the progression of chronic kidney disease (CKD) in Type 1 Diabetes Groop P-H (Helsinki, Finland)
09:30 – 09:50	Discussion

09:50 – 10:00 CET

Break

10:00 – 11:15 CET	
Identification of chronic kidney disease to guide therapeutic decision Chair: Topsever P (Istanbul, Turkey), Ji L (Beijing, China) in Cooperation with PCDE	
10:00 – 10:15	Self-rated knowledge and competence regarding the management of chronic kidney disease in primary care Topsever P (Istanbul, Turkey)
10:15 – 10:30	Shaping the role of primary care in diagnosis of CKD Itzhak B (Haifa, Israel)
10:30 – 10:45	Identifying people with CKD in primary care: the role of POCT in KDIGO Guidelines Jacob S (Villingen-Schwenningen, Germany)
10:45 – 11:00	Diagnosing CKD with UACR in China - Paving the Way for Effective Treatment Yu X (Tongji, China)
11:00 – 11:15	Discussion

11:15 – 11:30 CET	Break
--------------------------	--------------

11:30 – 12:30 CET	
Current considerations in the management of CKD Chair: Heerspink H (Groningen, Netherlands), Fernández-Fernández B (Madrid, Spain)	
11:30 – 11:50	SGLT-2 inhibitors in CKD: new outcomes to strengthen the bridge to clinical care Heerspink H (Groningen, Netherlands)
11:50 – 12:10	Non-steroidal MRAs: recent and future perspectives Rossing P (Copenhagen, Denmark)
12:10– 12:30	Discussion

12:30 – 13:15 CET	
Heart failure and Cardiovascular Risk Chair: Ceriello A (Milan, Italy), Škrha J (Prague, Czech Republic)	
12:30 – 12:45	Current and future aspects of heart failure management Kosiborod M (Kansas City, USA)
12:45 – 13:00	CLEAR Outcomes: Reducing cardiovascular mortality and morbidity with bempedoic acid Ray KK (London, UK)
13:00 – 13:15	Discussion

13:15 – 13:45 CET	Break
--------------------------	--------------

13:45 – 14:30 CET	
Cancer – an emerging, yet largely underrecognized important topic in metabolic diseases Chair: Ceriello A (Milan, Italy), Ibrahim M (Charlotte, USA)	
13:45 – 14:00	Type 2 Diabetes & Cancer Standl E (Munich, Germany)
14:00 – 14:15	Obesity & Cancer Herzig S (Munich, Germany)
14:15 – 14:30	Discussion

14:30 – 16:15 CET	
Diabetes, Obesity and NASH – Discovering the New Now Chairs: Forst T (Mainz, Germany), Rodbard H (Rockville, USA)	
14:30 – 14:50	Recent advances in incretin therapy Frías JP (Los Angeles, USA)
14:50 – 15:10	Successful treatment of Type 2 Diabetes and obesity: managing cardiovascular risk and implementing new treatment pathways Vilsbøll T (Copenhagen, Denmark)
15:10 – 15:30	Diagnosis, prognosis and future treatments options of fatty liver disease Tacke F (Berlin, Germany)
15:30 – 15:50	How to communicate successfully with people who are obese Snoek F (Amsterdam, Netherlands)
15:50 – 16:15	Discussion

16:15 – 16:30 CET Break

16:30 – 17:30 CET

Industry’s perspective - panel discussion

17:30 – 18:30 CET

Oral Presentations – Part 2

Chairs: Forst T (Mainz, Germany), Mankovsky B (Kyiv, Ukraine)

17:30 – 18:30 CET

OP 6: Change in Fibrosis-4 Index (FIB4) is Associated With Risk of Liver Events, Cardiovascular Events, and All-Cause Mortality in Patients With Obesity and/or Type 2 Diabetes (T2D)

Jara M (New Jersey, USA)

OP 7: Prevalence and Effect of Semaglutide on Non-Alcoholic Steatohepatitis in People With Obesity With and Without Type 2 Diabetes: Analyses From the STEP 1 and 2 Trials Using SomaSignal Tests

Long M (Søborg, Denmark)

OP 8: Heart Failure in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease With and Without Cardiovascular Autonomic Neuropathy

Monashnenko O (Kyiv, Ukraine)

OP 9: Glycaemic Control in Users of Automated Insulin Delivery Systems Increased Slightly From 2019 to 2021: Longitudinal Data of the Digitalisation and Technology Report

Ehrmann D (Bad Mergentheim, Germany)

OP 10: Real-World Evidence Showing Sustained Improvements in Glycemia at 1 Year in People With Type 2 Diabetes Using the OneTouch Reveal® Mobile App With OneTouch® Blood Glucose Meters

Holt E (Malvern, USA)

18:30 – 18:45 CET

Abstract Awards and Closing

Schnell O (Munich, Germany)